Lario Therapeutics Secures $6 Million MJFF Grant for Groundbreaking Parkinson’s Research

Edinburgh (United Kingdom) – Lario Therapeutics Ltd, a preclinical stage biotech and Golgi Neurosciences’ portfolio company developing first-in-class precision medicines targeting disease-modifying treatments for severe neurological disorders, has achieved a remarkable milestone by securing a $6 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

This substantial award will fund Lario’s innovative preclinical program investigating selective CaV2.3 calcium channel inhibition as a novel and potentially disease-modifying therapy for Parkinson’s disease.

For more information see Lario Therapeutics web page and Golgi Neurosciences’ Linkedin Page.